Trastuzumab Deruxtecan in Previously Treated HER2-Positive Breast Cancer

In this single-group, phase 2 study, the use of trastuzumab deruxtecan resulted in a response in 60% of women with HER2-positive advanced breast cancer who had received a median of six previous lines of therapy. The drug was associated with myelosuppression and gastrointestinal toxicity; interstitia...

Celý popis

Uloženo v:

Podrobná bibliografie
Vydáno v:	The New England journal of medicine Ročník 382; číslo 7; s. 610 - 621
Hlavní autoři:	Modi, Shanu, Saura, Cristina, Yamashita, Toshinari, Park, Yeon Hee, Kim, Sung-Bae, Tamura, Kenji, Andre, Fabrice, Iwata, Hiroji, Ito, Yoshinori, Tsurutani, Junji, Sohn, Joohyuk, Denduluri, Neelima, Perrin, Christophe, Aogi, Kenjiro, Tokunaga, Eriko, Im, Seock-Ah, Lee, Keun Seok, Hurvitz, Sara A, Cortes, Javier, Lee, Caleb, Chen, Shuquan, Zhang, Lin, Shahidi, Javad, Yver, Antoine, Krop, Ian
Médium:	Journal Article
Jazyk:	angličtina
Vydáno:	United States Massachusetts Medical Society 13.02.2020
Témata:	Adult Aged Aged, 80 and over Antibodies, Monoclonal, Humanized - administration & dosage Antibodies, Monoclonal, Humanized - adverse effects Antineoplastic Combined Chemotherapy Protocols - adverse effects Antineoplastic Combined Chemotherapy Protocols - therapeutic use Antitumor activity Body weight Breast cancer Breast Neoplasms - drug therapy Breast Neoplasms - mortality Breast Neoplasms - pathology Camptothecin - administration & dosage Camptothecin - adverse effects Camptothecin - analogs & derivatives Confidence intervals Consolidation Chemotherapy Cytotoxicity DNA topoisomerase Drug dosages Epidermal growth factor ErbB-2 protein Female Humans Immunoconjugates - administration & dosage Immunoconjugates - adverse effects Immunotherapy Intention to Treat Analysis Kaplan-Meier Estimate Lung diseases Lung Diseases, Interstitial - chemically induced Metastases Metastasis Middle Aged Monoclonal antibodies Myelosuppression Nausea Patients Progression-Free Survival Receptor, ErbB-2 - analysis Receptor, ErbB-2 - antagonists & inhibitors Targeted cancer therapy Trastuzumab Tumors
ISSN:	0028-4793, 1533-4406, 1533-4406
On-line přístup:	Získat plný text
Tagy:	Přidat tag Žádné tagy, Buďte první, kdo vytvoří štítek k tomuto záznamu!

Buďte první, kdo okomentuje tento záznam!